The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Self-citationRonco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Self-citationA 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Self-citationHPV Screening for Cervical Cancer in Rural India
Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh, A. M., Hingmire, S., Malvi, S. G., Thorat, R., Kothari, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808516 · Cited by 1,321
Guan, P., Howell‐Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27485 · Cited by 927
Self-citationArbyn, M., Kyrgiou, M., Simoens, C., Raifu, A. O., Koliopoulos, G., Martin-Hirsch, P., Prendiville, W., & Paraskevaidis, E. (2008) · BMJ · doi:10.1136/bmj.a1284 · Cited by 694
Self-citationArbyn, M., Verdoodt, F., Snijders, P. J. F., Verhoef, V. M. J., Suonio, E., Dillner, L., Minozzi, S., Bellisario, C., Banzi, R., Zhao, F.-H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70570-9 · Cited by 674
Self-citationWhich high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275
Self-citation
Research works printed but not linked: 121
- de Sanjosé, S. et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur. J. Cancer 49, 3450–3461 (2013). · DOI · Paper page
- Alemany, L. et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur. J. Cancer 50, 2846–2854 (2014). · DOI · Paper page
- Alemany, L. et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int. J. Cancer 136, 98–107 (2015). · DOI · Paper page
- Mork, J. et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125–1131 (2001). · DOI · Paper page
- Forman, D. et al. Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl. 5), F12–F23 (2012). · DOI · Paper page
- Cornall, A. M. et al. Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with “low-risk” HPV genotypes 6 and 11. Int. J. Cancer 133, 2253–2258 (2013). · DOI
- Ferlay, J. et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. WHO International Agency for Research on Cancer [online] , (2010).
- Parkin, D. M. & Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl. 3), 11–25 (2006). · DOI · Paper page
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. WHO International Agency for Research on Cancer [online] , (2013).
- Vaccarella, S., Lortet-Tieulent, J., Plummer, M., Franceschi, S. & Bray, F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur. J. Cancer 49, 3262–3273 (2013). · DOI · Paper page
- Vaccarella, S. et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br. J. Cancer 111, 965–969 (2014). · DOI · Paper page
- WHO International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening 10, (IARC Press, 2005).
- Salo, H. et al. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. Int. J. Cancer 133, 1459–1469 (2013). · DOI
- Salo, H. et al. Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland. Int. J. Cancer 135, 204–213 (2014). · DOI
- Habbema, D., De Kok, I. M. & Brown, M. L. Cervical cancer screening in the United States and the Netherlands: a tale of two countries. Milbank Q. 90, 5–37 (2012). · DOI
- Cuzick, J. et al. New technologies and procedures for cervical cancer screening. Vaccine 30 (Suppl. 5), F107–F116 (2012). · DOI
- Arbyn, M. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl. 5), F88–F99 (2012). · DOI · Paper page
- Arbyn, M. et al. Cervical cancer screening program and human papillomavirus (HPV) testing, part II: update on HPV primary screening. (Belgian Health Care Knowledge Centre [KCE], 2015). · doi:10.57598/r238c
- Steben, M. et al. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries. Vaccine 30 (Suppl. 5), F183–F191 (2012). · DOI
- Meijer, C. J. et al. in The Epidemiology of Cervical Cancer and Human Papillomavirus (eds Muñoz, N., Bosch, F. X., Shah, K. V. & Meheus, A.) 271–281 (International Agency for Research on Cancer, 1992).
- Cuzick, J. et al. Human papillomavirus testing in primary cervical screening. Lancet 345, 1533–1536 (1995). · DOI · Paper page
- Cuzick, J. et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology—results from the Hammersmith study. Int. J. Cancer 122, 2294–2300 (2008). · DOI
- Naucler, P. et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357, 1589–1597 (2007). · DOI · Paper page
- Rijkaart, D. C. et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13, 78–88 (2012). · DOI · Paper page
- Kitchener, H. C. et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10, 672–682 (2009). · DOI · Paper page
- Ronco, G. et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249–257 (2010). · DOI · Paper page
- Wright, T. C. et al. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int. J. Cancer 134, 1835–1843 (2014). · DOI
- Franco, E. L., Mahmud, S. M., Tota, J., Ferenczy, A. & Coutlée, F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40, 478–485 (2009). · DOI
- Dijkstra, M. G. et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann. Oncol. 25, 927–935 (2014). · DOI
- Ronco, G. et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors [Italian]. Epidemiol. Prev. 36, e1–e72 (2012).
- Torné Bladé, A. et al. Guía de cribado del cáncer de cuello de útero en España, 2014. Prog. Obstet. Ginecol. 57 (Suppl. 1), 1–53 (2014). · doi:10.1016/s0304-5013(14)73068-7
- Huh, W. K. et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet. Gynecol. 125, 330–337 (2015). · DOI · Paper page
- von Karsa, L. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. http://dx.doi.org/10.1016/j.pvr.2015.06.006 (2015). · DOI · Paper page
- Leinonen, M. et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101, 1612–1623 (2009). · DOI · Paper page
- Carozzi, F. et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9, 937–945 (2008). · DOI · Paper page
- Petry, K. U. et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 121, 505–509 (2011). · DOI · Paper page
- Uijterwaal, M. H. et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int. J. Cancer 136, 2361–2368 (2015). · DOI
- Schiffman, M. et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J. Clin. Microbiol. 53, 52–59 (2015). · DOI
- Verhoef, V. M. et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 15, 315–322 (2014). · DOI · Paper page
- Cuzick, J., Mayrand, M. H., Ronco, G., Snijders, P. & Wardle, J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 (Suppl. 3), 90–97 (2006). · DOI
- Cuzick, J. et al. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J. Clin. Virol. 60, 44–49 (2014). · DOI
- Denny, L. et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294, 2173–2181 (2005). · DOI · Paper page
- Kyrgiou, M. et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367, 489–498 (2006). · DOI · Paper page
- McCaffery, K., Waller, J., Nazroo, J. & Wardle, J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. Sex. Transm. Infect. 82, 169–174 (2006). · DOI · Paper page
- Kwan, T. T. et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet. Gynecol. Scand. 90, 445–451 (2011). · DOI
- Hendry, M. et al. Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. Br. J. Cancer 107, 243–254 (2012). · DOI
- Qiao, Y.-L. et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int. J. Cancer 134, 2891–2901 (2014). · DOI
- Chen, W. et al. The concordance of HPV DNA detection by Hybrid Capture 2 and care HPV on clinician- and self-collected specimens. J. Clin. Virol. 61, 553–557 (2014). · DOI
- Pathak, N., Dodds, J., Zamora, J. & Khan, K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 349, g5264 (2014). · DOI · Paper page
- Castle, P. E. et al. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. Am. J. Clin. Pathol. 143, 126–133 (2015). · DOI
- Schiller, J. T., Castellsagué, X. & Garland, S. M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30 (Suppl. 5), F123–F138 (2012). · DOI · Paper page
- Lehtinen, M. & Dillner, J. Clinical trials of human papillomavirus vaccines and beyond. Nat. Rev. Clin. Oncol. 10, 400–410 (2013). · DOI · Paper page
- Stillo, M., Carrillo Santisteve, P. & Lopalco, P. L. Safety of human papillomavirus vaccines: a review. Expert Opin. Drug Saf. 14, 697–712 (2015). · DOI
- Herrero, R. et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS ONE 8, e68329 (2013). · DOI · Paper page
- Garland, S. M. The Australian experience with the human papillomavirus vaccine. Clin. Ther. 36, 17–23 (2014). · DOI
- Hariri, S. et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine 33, 1608–1613 (2015). · DOI
- Baldur-Felskov, B., Dehlendorff, C., Munk, C. & Kjaer, S. K. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J. Natl Cancer Inst. 106, djt460 (2014). · DOI · Paper page
- Drolet, M. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 15, 565–580 (2015). · DOI · Paper page
- Tabrizi, S. N. et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect. Dis. 14, 958–966 (2014). · DOI · Paper page
- Lehtinen, M. et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89–99 (2012). · DOI · Paper page
- Mesher, D. et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 32, 26–32 (2013). · DOI
- Malagón, T. et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Medicine (Baltimore) 94, e722 (2015). · DOI
- David, M.-P. et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol. 115, S1–S6 (2009). · DOI
- Aregay, M., Shkedy, Z., Molenberghs, G., David, M.-P. & Tibaldi, F. Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach. J. Biopharm. Stat. 23, 1228–1248 (2013). · doi:10.1080/10543406.2013.834917
- Markowitz, L. E. et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56, 1–24 (2007).
- Giuliano, A. R. et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N. Engl. J. Med. 364, 401–411 (2011). · DOI · Paper page
- Palefsky, J. M. et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365, 1576–1585 (2011). · DOI · Paper page
- Castellsagué, X. et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br. J. Cancer 105, 28–37 (2011). · DOI · Paper page
- Skinner, S. R. et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 384, 2213–2227 (2014). · DOI · Paper page
- Kim, J. J., Brisson, M., Edmunds, W. J. & Goldie, S. J. Modeling cervical cancer prevention in developed countries. Vaccine 26 (Suppl. 10), K76–K86 (2008). · DOI
- Markowitz, L. E. et al. Human papillomavirus vaccine introduction--the first five years. Vaccine 30 (Suppl. 5), F139–F148 (2012). · DOI · Paper page
- Elfström, K. M., Dillner, J. & Arnheim-Dahlström, L. Organization and quality of HPV vaccination programs in Europe. Vaccine 33, 1673–1681 (2015). · doi:10.1016/j.vaccine.2015.02.028
- Franco, E. L., Cuzick, J., Hildesheim, A. & de Sanjosé, S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 (Suppl. 3), 171–177 (2006). · DOI · Paper page
- Tota, J. E., Ramana-Kumar, A. V., El-Khatib, Z. & Franco, E. L. The road ahead for cervical cancer prevention and control. Curr. Oncol. 21, e255–e264 (2014). · DOI
- Kjaer, S. K., Frederiksen, K., Munk, C. & Iftner, T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102, 1478–1488 (2010). · DOI · Paper page
- de Sanjose, S. et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol. Biomarkers Prev. 22, 1313–1318 (2013). · DOI · Paper page
- Hildesheim, A. et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298, 743–753 (2007). · DOI · Paper page
- Gertig, D. M. et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 11, 227 (2013). · DOI · Paper page
- Lehtinen, M. et al. Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. Vaccine 33, 1284–1290 (2015). · DOI
- Edgren, G. & Sparén, P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 8, 311–316 (2007). · DOI · Paper page
- Kang, W. D., Choi, H. S. & Kim, S. M. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecol. Oncol. 130, 264–268 (2013). · DOI · Paper page
- Rodríguez, A. C. et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J. Natl Cancer Inst. 102, 315–324 (2010). · DOI · Paper page
- Castañón, A., Landy, R., Cuzick, J. & Sasieni, P. Cervical screening at age 50–64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 11, e1001585 (2014). · DOI
- Gravitt, P. E. The known unknowns of HPV natural history. J. Clin. Invest. 121, 4593–4599 (2011). · DOI · Paper page
- Gravitt, P. E. Evidence and impact of human papillomavirus latency. Open Virol. J. 6, 198–203 (2012). · DOI
- Trottier, H. et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 70, 8569–8577 (2010). · DOI · Paper page
- Veldhuijzen, N. J., Snijders, P. J., Reiss, P., Meijer, C. J. & van de Wijgert, J. H. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect. Dis. 10, 862–874 (2010). · DOI · Paper page
- Safaeian, M. et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J. Natl Cancer Inst. 102, 1653–1662 (2010). · DOI · Paper page
- Castellsagué, X. et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J. Infect. Dis. 210, 517–534 (2014). · DOI
- Dempsey, A. F., Brewer, S. E., Pyrzanowski, J., Sevick, C. & O'leary, S. T. Acceptability of human papillomavirus vaccines among women older than 26 years. Vaccine 33, 1556–1561 (2015). · doi:10.1016/j.vaccine.2015.02.018
- Marshall, H., Ryan, P., Roberton, D. & Baghurst, P. A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust. N. Z. J. Public Health 31, 235–242 (2007). · DOI
- Cui, Y., Baldwin, S. B., Wiley, D. J. & Fielding, J. E. Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am. J. Prev. Med. 39, 559–563 (2010). · doi:10.1016/j.amepre.2010.08.001
- Agorastos, T. et al. Distinct demographic factors influence the acceptance of vaccination against HPV. Arch. Gynecol. Obstet. 292, 197–205 (2015). · DOI
- Anhang Price, R., Koshiol, J., Kobrin, S. & Tiro, J. A. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 29, 4238–4243 (2011). · DOI
- Lazcano-Ponce, E., Alonso, P., Ruiz-Moreno, J. A. & Hernández-Avila, M. Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Pública México 45 (Suppl. 3), S449–S462 (2003). · DOI
- Almonte, M. et al. New paradigms and challenges in cervical cancer prevention and control in Latin America [Spanish]. Salud Pública México 52, 544–559 (2010). · DOI
- Poljak, M. et al. Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 31 (Suppl. 7), H80–H82 (2013). · DOI
- Dasbach, E. J., Largeron, N. & Elbasha, E. H. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev. Pharmacoecon. Outcomes Res. 8, 491–500 (2008). · DOI
- Kim, J. J. & Goldie, S. J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359, 821–832 (2008). · DOI · Paper page
- Usher, C. et al. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26, 5654–5661 (2008). · DOI
- Dasbach, E. J., Insinga, R. P. & Elbasha, E. H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115, 947–956 (2008). · DOI
- Jit, M., Choi, Y. H. & Edmunds, W. J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337, a769 (2008). · DOI · Paper page
- Kim, J. J., Ortendahl, J. & Goldie, S. J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann. Intern. Med. 151, 538–545 (2009). · DOI
- Elbasha, E. H., Dasbach, E. J., Insinga, R. P., Haupt, R. M. & Barr, E. Age-based programs for vaccination against HPV. Value Health 12, 697–707 (2009). · DOI
- Dasbach, E. J., Nagy, L., Brandtmüller, A. & Elbasha, E. H. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J. Med. Econ. 13, 110–118 (2010). · doi:10.3111/13696990903546013
- Olsen, J. & Jepsen, M. R. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int. J. Technol. Assess. Health Care 26, 183–191 (2010). · DOI
- Westra, T. A. et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J. Infect. Dis. 204, 377–384 (2011). · DOI
- Demarteau, N., Detournay, B., Tehard, B., El Hasnaoui, A. & Standaert, B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int. J. Public Health 56, 153–162 (2011). · DOI
- Bogaards, J. A., Coupé, V. M. H., Meijer, C. J. L. M. & Berkhof, J. The clinical benefit andcost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 29, 8929–8936 (2011). · doi:10.1016/j.vaccine.2011.09.055
- Demarteau, N., Van Kriekinge, G. & Simon, P. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine 31, 3962–3971 (2013). · DOI
- Turner, H. C., Baussano, I. & Garnett, G. P. Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine. PLoS ONE 8, e75552 (2013). · DOI
- Baussano, I., Lazzarato, F., Ronco, G., Dillner, J. & Franceschi, S. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. Int. J. Cancer 133, 1876–1881 (2013). · DOI
- Baussano, I., Dillner, J., Lazzarato, F., Ronco, G. & Franceschi, S. Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect. Agent. Cancer 9, 4 (2014). · doi:10.1186/1750-9378-9-4
- Burger, E. A., Sy, S., Nygård, M., Kristiansen, I. S. & Kim, J. J. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS ONE 9, e89974 (2014). · DOI
- Jit, M., Brisson, M., Laprise, J.-F. & Choi, Y. H. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 350, g7584 (2015). · DOI
- Lazcano-Ponce, E. et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int. J. Cancer 135, 109–116 (2014). · DOI
- HPV 2015. 30th International Papillomavirus Conference, September 17–21, 2015, Lisbon, Portugal [online] , (2015).
- Bruni, L. et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202, 1789–1799 (2010). · DOI · Paper page
- Kyrgiou, M. et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat. Rev. 32, 516–523 (2006). · DOI
- McCredie, M. R. et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 9, 425–434 (2008). · DOI · Paper page
- Muñoz, N. et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373, 1949–1957 (2009). · DOI · Paper page
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Worldwide burden of cancer attributable to HPV by site, country and HPV type
de Martel, C., Plummer, M., Vignat, J., & Franceschi, S. (2017) · International Journal of Cancer · doi:10.1002/ijc.30716 · Cited by 2,322
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
Self-citation
Metadata
- Authors
- Bosch, F. X., Robles, C., Díaz, M., Arbyn, M., Baussano, I., Clavel, C., Ronco, G., Dillner, J., Lehtinen, M., Petry, K.-U., Poljak, M., Kjaer, S. K., Meijer, C. J. L. M., Garland, S. M., Salmerón, J., Castellsagué, X., Bruni, L., de Sanjosé, S., & Cuzick, J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 2
- Pages
- 119-132
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1275532855
- Cited by
- 206
- References
- 8
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HPV-FASTER: broadening the scope for prevention of HPV-related cancer. https://app.cochat.ai/papers/10.1038/nrclinonc.2015.146
- The paper
- Bosch, F. X., Robles, C., Díaz, M., Arbyn, M., Baussano, I., Clavel, C., Ronco, G., Dillner, J., Lehtinen, M., Petry, K.-U., Poljak, M., Kjaer, S. K., Meijer, C. J. L. M., Garland, S. M., Salmerón, J., Castellsagué, X., Bruni, L., de Sanjosé, S., & Cuzick, J. (2016). HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nature Reviews Clinical Oncology. https://doi.org/10.1038/nrclinonc.2015.146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.